Long-term impact of the 70-gene signature on breast cancer outcome

Publication Name: Breast Cancer Research and Treatment

Author(s): C. A. Drukker, H. van Tinteren, M. K. Schmidt, E. J. Th. Rutgers, R. Bernards, M. J. van de Vijver, L. J. van’t Veer

Several studies have validated the prognostic value of the 70-gene prognosis signature (MammaPrintR), but long-term outcome prediction of these patients has not been previously reported. The follow-up of the consecutively treated cohort of 295 patients (<53 years) with invasive breast … Continued

MammaPrint Molecular Diagnostics on Formalin-Fixed, Paraffin-Embedded Tissue.

Publication Name: The Journal of Molecular Diagnostics

Author(s): Sapino A, Roepman P, Linn SC, Snel MHJ, Delahaye LJMJ, van den Akker J, Glas AM, Simon IM, Barth N, de Snoo FA, van 't Veer LJ, Molinaro L, Berns EMJJ, Wesseling J, Riley LB, Anderson D, Nguyen B, Cox

MammaPrint, a prognostic 70-gene profile for early-stage breast cancer, has been available for fresh tissue. Improvements in RNA processing have enabled microarray diagnostics for formalin-fixed, paraffin- embedded (FFPE) tissue. Here, we describe method optimization, validation, and performance of MammaPrint using … Continued

Performance Characteristics of the MammaPrint Breast Cancer Diagnostic Gene Signature

Publication Name: Personalized Medicine

Author(s): Leonie JM Delahaye, Diederik Wehkamp, Arno N Floore, Rene Bernards, Laura J van‘t Veer1 & Annuska M Glas

The analytical performance of multigene signatures depends on many parameters, including precision, repeatability, reproducibility and intratumor heterogeneity. Indicators such as sensitivity, specificity, positive predictive value and negative predictive value are typically used to define the clinical performance of a diagnostic … Continued

Estrogen receptor splice variants as a potential source of false-positive estrogen receptor status in breast cancer diagnostics

Publication Name: Breast Cancer Research and Treatment

Author(s): Groenendijk, Wilbert Zwart, Arno Floore, Stephanie Akbari, Rene Bernards

It is well established that only estrogen receptor (ER)-positive tumors benefit from hormonal therapies. We hypothesized that a subgroup of breast cancer patients expresses estrogen receptor a (ERa), but fails to respond to hormonal therapy due to the expression of … Continued

Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy

Publication Name: Breast Cancer Research and Treatment

Author(s): Stefan Glück, Femke de Snoo, Justine Peeters, Lisette Stork-Sloots, George Somlo

The aim of this study was to analyze the correlation between the pathologic complete response (pCR) rate after neoadjuvant chemotherapy and long-term outcome (distant metastases-free survival [DMFS]) in patients with early-stage breast cancer using BluePrint and MammaPrint molecular subtyping versus … Continued

A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study

Publication Name: International Journal of Cancer

Author(s): C.A. Drukker, J.M. Bueno-de-Mesquita, V.P. Retèl, W.H. van Harten, H. van Tinteren, J. Wesseling, R.M.H. Roumen, M. Knauer, L.J. van ’t Veer, G.S. Sonke, E.J.T. Rutgers, M.J. van de Vijver, S.C. Linn

The 70-gene signature (MammaPrint™) has been developed on retrospective series of breast cancer patients to predict the risk of breast cancer distant metastases. The microarRAy-prognoSTics-in-breast-cancER (RASTER) study was the first study designed to prospectively evaluate the performance of the 70-gene … Continued

Independent Validation of a Prognostic Genomic Signature (ColoPrint) for Patients With Stage II Colon Cancer

Publication Name: Annals of Surgery

Author(s): Matthias Maak, MD, Iris Simon, PhD, Ulrich Nitsche, MD, Paul Roepman, PhD, Mireille Snel, MSc Annuska M. Glas, PhD

  Objectives: The aim of this study was to independently validate a genomic signature developed both to assess recurrence risk in stage II patients and to assist in treatment decisions.   Background: Adjuvant therapy is recommended for high-risk patients with … Continued

Cost Effectiveness of Gene Expression Profiling for Early Stage Breast Cancer

Publication Name: Cancer

Author(s): Mo Yang, MS; Suja Rajan, PhD; and Amalia M. Issa, PhD, MPH

BACKGROUND: Gene expression profiling (GEP) is being used increasingly for risk stratification to identify women with lymph nodenegative, estrogen receptor-positive, early stage breast cancer who are most likely to benefit from adjuvant chemotherapy. The authors of this report evaluated the … Continued

Comparison of Molecular Subtyping with BluePrint, MammaPrint, and TargetPrint to Local Clinical Subtyping in Breast Cancer Patients

Publication Name: Annals of Surgical Oncology

Author(s): Bichlien Nguyen, Pino G. Cusumano, Kenneth Deck, Deborah Kerlin, Agustin A. Garcia, Julie L. Barone, Edgardo Rivera, Katharine Yao, Femke A. de Snoo, Jeroen van den Akker, Lisette Stork-Sloots, Daniele Generali

Purpose: To compare breast cancer subtyping with the three centrally assessed microarray-based assays BluePrint, MammaPrint, and TargetPrint with locally assessed clinical subtyping using immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). Methods: BluePrint, MammaPrint, and TargetPrint were all performed on … Continued

The EORTC 10041/BIG 03-04 MINDACT trial is feasible: Results of the pilot phase

Publication Name: EUROPEAN JOURNAL OF CANCER

Author(s): Emiel Rutgers, Martine J. Piccart-Gebhart, Jan Bogaerts, Suzette Delaloge, Laura Van ‘t Veer

Background: The MINDACT (Microarray In Node-negative and 1–3 node positive Disease may Avoid ChemoTherapy) trial investigates the clinical utility of the 70-gene profile (MammaPrint) for the selection of breast cancer patients for adjuvant chemotherapy (CT) together with standard clinicopathological criteria. … Continued